Wisp and Vesalius Longevity Labs Partner to Launch Peptide Therapeutics Designed to Address Women’s Health Needs
Wisp andVesalius Longevity Labs Partner to Launch Peptide Therapeutics Designed toAddress Women’s Health Needs
The Leading Women’s Telehealth Provider EntersLongevity, Bringing Accessible, High-Quality Solutions to Male-Dominated Market
NEW YORK – Oct 9, 2025 – Wisp, the largest pure play women's telehealth company in the U.S., todayannounced a strategic partnership with Vesalius Longevity Labs, the market’s first soon-to-bepublicly-traded company dedicated exclusively to longevity science. The companybehind Peptual, a premium line of peptides and bioregulators, Vesalius willwork with Wisp to develop an exclusive range of peptide therapies designed toadvance women’s quality of life and promote longevity.
Theglobal peptide therapeutics market is valued at $43.1 billion and is projected to reach $106 billion by 2033. While peptides have been used for decadesto treat metabolic illnesses, their recent surge in popularity has been largelydriven by men seeking optimized health and performance. Now, Vesalius and Wispare coming together at the forefront of this commanding trend, unlockingsolutions designed around women’s unique biology and effectively doubling themarket opportunity.
“Womenmake up half the population, yet they’ve been treated like an afterthought inthe longevity space,” shares Monica Cepak, CEO of Wisp. “Our mission is toclose that gap by making advanced therapeutics both accessible and affordablefor women at every stage of life. By partnering with Vesalius, we’reintroducing peptides into women’s healthcare and expanding access to a powerfultool that can transform how women age.”
Drawingon Vesalius’ existing Peptual product line of primarily US-sourced injectables,patches, nasal sprays, oral and topical formulations this partnership willoffer a comprehensive product portfolio designed to address women’s lifestages, such as fertility and menopause. Beyond product innovation, Wisp andVesalius will also jointly evaluate emerging longevity AI platforms forpotential integration into their services, exploring opportunities forstrategic investment in AI tools that enhance personalized care, clinicaldecision support, and patient engagement.
“Ourproduct innovation team and globally recognized Scientific Advisory Board arecommitted to working closely with Wisp to accelerate access to safe, effectivesolutions,” offers Kevin Rabbitt, CEO of Vesalius Longevity Labs. “By combiningVesalius’ expertise in longevity science with Wisp’s leadership in women’shealthcare, we’re ushering in a new era that will meaningfully extend women’slifespan.”
Setto launch at the top of 2026, this partnership reflects Wisp’s broader strategyto redefine women’s healthcare. Following this week’s entrance into thelongevity category with the launch of two science-backed supplements— Wisp Thrive Creatine Tablets and Wisp Revive Collagen Tablets — the company continues to build on its foundation,establishing its long-term presence across key health verticals. Leveragingstrategic partnerships with category leaders like Vesalius, Wisp is creatingthe next generation of women’s healthcare — bringing innovative treatmentoptions to market and ensuring women have access to the same cutting-edgesolutions shaping the future of care.
###
About Wisp:
Wispis the largest pure play women’s telehealth provider in the U.S., serving morethan 1.5 million patients nationwide. Offering discreet, online care and acomprehensive range of first-to-market products, Wisp addresses women’s healthneeds across every stage of life—from birth control to fertility, menopause,STI testing, and more. Recognized by Fast Company as one of the Most InnovativeCompanies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-ownedby WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.
About Vesalius Labs:
Vesalius Longevity Labs is a next-generation health and wellnesscompany at the forefront of longevity science. Guided by clinical researchers,physicians, and biotech veterans, Vesalius harnesses the power of peptideinnovation to deliver advanced products and services grounded instate-of-the-art research. Through a global, end-to-end B2Doctor ecosystem,Vesalius offers a comprehensive portfolio of injectables, patches, nasalsprays, oral, and topical formulations—primarily U.S.-sourced and manufacturedin FDA-registered, cGMP-compliant facilities.
Media Contact:
Lilly Bromberg
SolComms